Dr Reddys Laboratories (RDY) Cash & Equivalents (2009 - 2026)

Dr Reddys Laboratories has reported Cash & Equivalents for 18 years, with the latest figure at $118.3 million in Q2 2026.

• On a quarterly basis, Cash & Equivalents rose 12.49% year-over-year to $118.3 million in Q2 2026; TTM through Jun 2026 was $118.3 million, a 12.49% increase from a year earlier, with the FY2026 full-year figure at $164.0 million, down 4.65% from the prior year.
• Cash & Equivalents was $118.3 million for Q2 2026 at Dr Reddys Laboratories, down from $168.1 million in the prior quarter.
• The five-year high for Cash & Equivalents was $209.5 million in Q4 2025, with the low at $58.9 million in Q2 2024.
• Average Cash & Equivalents over 5 years is $122.2 million, with a median of $113.8 million recorded in 2022.
• The sharpest annual moves came in 2022 and 2025: Cash & Equivalents plunged 74.01% in 2022, then jumped 97.74% in 2025.
• Over 5 years, Cash & Equivalents stood at $76.2 million in 2022, then climbed by 18.71% to $90.5 million in 2023, then surged by 70.56% to $154.3 million in 2024, then surged by 35.74% to $209.5 million in 2025, then tumbled by 43.51% to $118.3 million in 2026.
• The last three Cash & Equivalents figures came in at $118.3 million (Q2 2026), $168.1 million (Q1 2026), and $209.5 million (Q4 2025), per Business Quant data.